TM6SF2 and metabolic dysfunction-associated steatotic liver disease: Although genotyping of PNPLA3 and TM6SF2 variants is not routinely advised for NAFLD diagnosis, the EASL/EASD/EASO guidelines recommend their assessment in a selected group of patients [3].